# Allotex

**Canonical:** https://apis.io/providers/allotex/  
**Website:** https://us.allotex.com/  
**APIs profiled:** 6

Allotex Inc. is an ophthalmic biologics and medical device company headquartered at 27-43 Wormwood Street, Suite 160, Boston, Massachusetts, with European operations. Founded by Drs. Michael Mrochen and David Muller, it develops tissue-addition therapies for presbyopia, hyperopia and myopia. Its lead product, the Allotex TransForm corneal allograft, is a 20-micron-thick, 2.75mm-diameter disc of acellular human donor cornea shaped with an excimer laser under OCT measurement, sterilised by electron-beam radiation and shelf-stable for two years, implanted beneath a femtosecond-laser flap or on the corneal surface where it integrates with the patient's own cornea as, in the company's framing, a permanent living contact lens. Because the implant adds biocompatible human tissue rather than ablating tissue or inserting a synthetic inlay, the company positions the procedure as removable and replaceable. Allotex has run TransForm clinical trials for hyperopia and for intrastromal and sub-epithelial presbyopia correction, submitted an IDE to the U.S. FDA in May 2025 for its Allo-1 corneal implant, received FDA IDE approval for a U.S. presbyopia study in January 2026, and partners with Daicel High Performance Polymers and its TOPAS Advanced Polymers business on next-generation allograft technology. Allotex runs no developer program and publishes no product API, no developer portal, no API reference, no SDKs and no status page. The only machine-readable surface reachable without credentials is the WordPress REST content API behind us.allotex.com, catalogued here.

## Kin Score — 22.2 / 100 (emerging)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 22.2).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 18.8 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 25.5 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 26.3 (matched via tags).

## Agent readiness — 40.8 (agent-ready)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | yes |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (6)

- **Allotex Content API** — Pages, posts, reusable blocks and navigation.
- **Allotex Discovery API** — Route index, cross-content search and the oEmbed provider endpoint.
- **Allotex Identity API** — Public author records.
- **Allotex Media API** — The 218-item media library and its size variants.
- **Allotex Schema API** — Registered post types, taxonomies and statuses.
- **Allotex Taxonomy API** — Categories and tags.

## MCP servers (1)

- **allotex-mcp.yml**

## Security (2)

- **Allotex Authentication** — http · 1 scheme
- **Allotex Domain Security** — TLSv1.3 · DMARC

## Tags

Company, medical-devices, ophthalmology, biologics, vision-correction, corneal-allograft, presbyopia, hyperopia, refractive-surgery, tissue-processing, life-sciences, clinical-trials, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/allotex/). Scores are computed from the provider's own public artifacts under a published rubric.